Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRestructuring CostsRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Silence Therapeutics (SLN) EBIT: 2020-2025

Historic EBIT for Silence Therapeutics (SLN) over the last 6 years, with Sep 2025 value amounting to -$26.2 million.

  • Silence Therapeutics' EBIT rose 12.51% to -$26.2 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$83.0 million, marking a year-over-year decrease of 1.45%. This contributed to the annual value of -$63.3 million for FY2024, which is 1.65% up from last year.
  • Silence Therapeutics' EBIT amounted to -$26.2 million in Q3 2025, which was down 9.52% from -$24.0 million recorded in Q2 2025.
  • In the past 5 years, Silence Therapeutics' EBIT registered a high of -$4.4 million during Q4 2024, and its lowest value of -$30.0 million during Q3 2024.
  • Its 3-year average for EBIT is -$18.5 million, with a median of -$16.5 million in 2023.
  • Per our database at Business Quant, Silence Therapeutics' EBIT skyrocketed by 73.63% in 2024 and then tumbled by 409.03% in 2025.
  • MRQ analysis of 5 years shows Silence Therapeutics' EBIT stood at -$15.2 million in 2021, then increased by 15.32% to -$12.9 million in 2022, then fell by 28.39% to -$16.5 million in 2023, then skyrocketed by 73.63% to -$4.4 million in 2024, then crashed by 503.03% to -$26.2 million in 2025.
  • Its EBIT was -$26.2 million in Q3 2025, compared to -$24.0 million in Q2 2025 and -$28.4 million in Q1 2025.